#Osteoarthritic Pain Management Treatment Market Trends | Explore Tumblr posts and blogs

rohans18 · 2 years ago

Text

Perilymph Fistula Treatment Market Trends, Share, Competitive Dynamics, Demand - Forecast 2028

Global Perilymph Fistula Treatment Market, By Symptoms (Hearing loss, Vertigo, Tinnitus, Ear Pressure), Causes (Head Trauma, Barotrauma), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.

An expert team performs systematic, object-oriented and complete market research study to provide the facts associated with any subject in the field of marketing via Perilymph Fistula Treatment marketing report. The report has a lot to offer to both established and new players in the Perilymph Fistula Treatment industry with which they can completely understand the market. SWOT analysis and Porter’s Five Forces analysis methods are used wherever applicable, while generating this report. One of the most important parts of an international Perilymph Fistula Treatment market report is competitor analysis with which businesses can estimate or analyse the strengths and weaknesses of the competitors.

Key Players

The major players covered in the perilymph fistula treatment market report are Medtronic, Gem srl, biolitec AG, BD, Johnson & Johnson Services, Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, W. L. Gore & Associates, Bristol-Myers Squibb Company, Cook, KARL STORZ SE & Co. KG, Novartis AG, Boehringer Ingelheim International GmbH, AstraZeneca; Pfizer Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, ALLERGAN and Aurobindo Pharma among other domestic and global players. Osteoarthritic pain management treatment share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Browse More Info @ https://www.databridgemarketresearch.com/reports/global-perilymph-fistula-treatment-market

With the help of credible Perilymph Fistula Treatment market analysis report, businesses can make out the reaction of the consumers to an already existing product in the market. The report includes estimations of recent state of the market, CAGR values, market size and market share, revenue generation, and necessary changes required in the future products. A wide-ranging competitor analysis helps build superior strategies of production, improvement in certain product, its advertising or marketing and promotion for the business. Exhaustive and comprehensive market study performed in the wide ranging Perilymph Fistula Treatment market report offers current and forthcoming opportunities that put light on the future market investment.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Perilymph Fistula Treatment Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

0 notes

data-bridge-market-research · 6 years ago

Link

Market Analysis: Global Osteoarthritic Pain Management Treatment Market

Increase in the number of cases of Osteoarthritis is the rise in the geriatric population all over the world. This has left the industry with plenty of room to grow, because of the fact that there are no particular treatments available in the markets that are effective.

Market Definition: Global Osteoarthritic Pain Management Treatment Market

Osteoarthritis is a type of joint disorder that attacks the cartilage in between the bones and makes the joints swell up, red in color and making difficult for the joints to move properly. The usual symptoms of it are swelling, decrease in range of motion, and immobility in arms and legs specially when the spine is affected with osteoarthritis. All of the usual daily activities are affected.

Market Drivers

The government awareness programs about the disease has been considered a major factor in the improvement of the treatment market for Osteoarthritis

Increased knowledge and awareness amongst the people is causing the demand for the treatment to soar high, in turn increasing the growth of the industry

Increased healthcare affordability in the US will drive the market growth upwards as it makes the treatment accessible for the affected population

Market Restraints

Due to no permanent treatment available in the market, the industry is set to experience a restrictive market growth

Medicines or treatments are only available as of yet, to make the symptoms manageable and not the complete solution for the disease

Low per capita income in the still developing countries will be one of the major factors restricting the growth of the industry

Market Segmentation: Global Osteoarthritic Pain Management Treatment Market

Type

Diagnosis (Imaging)

Treatment

End-Users

Region

Hip

Wrist

Spinal

Finger Joints

Magnetic Resonance Imaging (MRI)

X-Rays

Medication (Analgesics, Non-Steroidal)

Surgery

Therapy

Hospitals

Clinics

Medical Institutes

Research Institutes

North America (US, Canada, Mexico)

Europe (Germany, UK, Italy, France, Spain)

Asia Pacific (China, India, Japan, Singapore, Australia, New Zealand)

South America (Brazil, Chile, Uruguay, Argentina)

Middle East & Africa (UAE, Saudi Arabia, South Africa, Qatar)

Key Developments in the Market: Global Osteoarthritic Pain Management Treatment Market

In September 2016, Pfizer Inc. captured the Medivation Inc. that is focused on the development of innovative therapies to the diseases that have only limited treatment options available in the market.

In December 2016, Pfizer also acquired the commercialization and development rights from AstraZeneca regarding the late-stage small molecule business, which will help in the regeneration of cartilage found ruptured or disrupted in Osteoarthritis

Competitive Analysis: Global Osteoarthritic Pain Management Treatment Market

The Global Osteoarthritic Pain Management Treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Osteoarthritic Pain Management Treatment market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Key Market Competitors: Global Osteoarthritic Pain Management Treatment Market

Pfizer Inc., AstraZeneca, Medivation Inc., Eli Lilly and Company, Abiogen Pharma S.p.A., Merck Sharp & Dohme Corp., Novartis AG, GlaxoSmithKline plc., Zimmer Biomet, Abbott Laboratories, Johnson & Johnson Services, Kolon TissueGene Inc., Ampio Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Abbott, AbbVie Inc., Astellas Pharma, BioDelivery Sciences International LLC., Crystal Genomics, Daiichi-Sankyo Company Limited, Endo Pharmaceuticals Inc., among others are the major Market players.

Research Methodology: Global Osteoarthritic Pain Management Treatment Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an Analyst Call or can drop down your inquiry

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Technological Writers, and Investors among others.

Supply Side: Product Managers, Marketing Managers, Distributors, Market Intelligence committees, Regulatory Authorities, Medical Institutes

Reasons to Purchase this Report

The report offers deep insights into the working structure of the market mechanisms and market segmentation

The report offers up the information on the different segments available in the market in this sector and the highest expected CAGR accordingly

Focuses on the market drivers and restraints and the growth factors associated with it

Customization of the Report

All segmentation provided above in this report is represented at country level.

All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

#Global Osteoarthritic Pain Management Treatment Market #Osteoarthritic Pain Management Treatment Market #Osteoarthritic Pain Management Treatment #Osteoarthritic Pain Management Treatment Market Size #Osteoarthritic Pain Management Treatment Market Share #Osteoarthritic Pain Management Treatment Market Trends #Osteoarthritic Pain Management Treatment Market Forecast

0 notes

healthcaredbmrnews · 2 years ago

Link

Data Bridge Market Research analyses that the osteoarthritic pain management treatment market is expected to reach the value of USD 15.34 billion by the year 2029, at a CAGR of 7.25% during the forecast period. The significant increase in the adoption of pain medications and growing awareness by government is a critical factor driving market growth.

0 notes

your-dietician · 3 years ago

Text

DUROLANE® Among High-Molecular Weight Hyaluronic Acid Treatments Linked to Significant Improvements in Knee Osteoarthritis Pain by American Academy of Orthopaedic Surgeons

New Post has been published on https://depression-md.com/durolane-among-high-molecular-weight-hyaluronic-acid-treatments-linked-to-significant-improvements-in-knee-osteoarthritis-pain-by-american-academy-of-orthopaedic-surgeons/

DUROLANE® Among High-Molecular Weight Hyaluronic Acid Treatments Linked to Significant Improvements in Knee Osteoarthritis Pain by American Academy of Orthopaedic Surgeons

DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) — Bioventus Inc., (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in innovations for active healing, announced that the American Academy of Orthopaedic Surgeons (AAOS) recently released updated clinical practice guidelines (CPG) indicating that high molecular weight cross-linked hyaluronic treatments, including Bioventus treatment DUROLANE, showed statistically significant improvement in certain knee osteoarthritis (OA) patients. The recommendation follows a review of 28 studies assessing intra-articular hyaluronic acid (HA) injections when compared to controls.

The CPG states that viscosupplementation, in the form of intra-articular HA injections, can represent a viable option for some patients who failed other treatments when appropriately indicated. Patients with low to moderate arthritic knees (Kellgren Lawrence (KL) I-III) have better results than those with severely affected knees (KL IV). In addition, the CPG highlights statistically significant results that were associated with high molecular weight cross-linked HA, but not with mid or low molecular weight HA.

DUROLANE is a single-injection osteoarthritis (OA) treatment that is lightly cross-linked and has the highest reported molecular weight of all US-approved HA products.1, 2

“These updated guidelines from AAOS now match how we have always recommended the utilization of our HA products for knee OA pain,” said John Nosenzo, Chief Commercial Officer, Bioventus. “Now patients and physicians will have even more confidence in using HA therapies with high molecular weight such as DUROLANE.”

“The updated clinical practice guidelines from AAOS better aligns with the clinical practice and experience of most physicians. HA injections, including DUROLANE, are a viable option for patients who fail treatments such as NSAID’s, weight loss, and exercise,” said Vinod Dasa MD. “We applaud the Academy for recognizing the patient population that benefits from these treatments to manage their low to moderate OA knee pain.”

Story continues

DUROLANE, which has more Level 1 clinical studies than any other single-injection HA, has demonstrated providing greater reduction in OA knee pain versus Synvisc-One®.3 It has longer lasting pain relief versus a steroid injection, is safe for repeated courses of therapy, and repeated use of DUROLANE does not increase the incidence of adverse events.4, 5 Visit www.durolane.com for more information.

About Bioventus Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatment & joint preservation, restorative therapies and bone graft substitutes. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and Twitter.

Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark. Synvisc-One is a registered trademark of Genzyme Corporation.

Indications for Use: DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen. Do not inject DUROLANE with knee joint infections, infections, or skin disease in the area of the injection site. Do not administer to patients with known hypersensitivity (allergy) to HA preparations. Risks can include transient pain or swelling at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children.

NOTE: The above indications presented are for the US market; indications may vary by country. Consult with your local Bioventus representative for approved use within your region of interest. Full prescribing information can be found in product labeling, at www.durolane.com or by contacting Bioventus Customer Service at 800-836-4080.

References: 1.Bioventus LLC. Q-Med Molecular Weight of DUROLANE, MA-10789. Data on ﬁle, RPT-001313. June 2021. 2.Nicholls M, Manjoo A, Shaw P, Niazi F, Rosen J. Rheological Properties of Commercially Available Hyaluronic Acid Products in the United States forth Treatment of Osteoarthritis Knee Pain. Clin Med Insights Arthritis Musculoskelet Disord. 2018 Jan 3;11:1179544117751622. doi: 10.1177/1179544117751622. PMID: 29326532; PMCID: PMC5757428. 3. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis. 2013; 2(1):108. doi:10.4172/2167-7921.1000108. 4 Leighton R, Åkermark C, Therrien R, et. al. NASHA® hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014; 22(1):17-25. 5. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2018.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements concerning the expected benefits, clinical development and market opportunities of DUROLANE. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release include, but are not limited to, statements about the adverse impacts on our business as a result of the COVID-19 pandemic; our dependence on a limited number of products; the continued and future acceptance of our existing portfolio of products and any new products, line extensions or expanded indications by physicians, patients, third-party payers and others in the medical community; our ability to differentiate the hyaluronic acid (“HA”) viscosupplementation therapies we own or distribute from alternative therapies for the treatment of osteoarthritic; the proposed down-classification of non-invasive bone growth stimulators, including our Exogen system, by the U.S. Food and Drug Administration (“FDA”); our ability to achieve and maintain adequate levels of coverage and/or reimbursement for our products, the procedures using our products, or any future products we may seek to commercialize; our ability to complete acquisitions or successfully integrate new businesses, products or technologies in a cost-effective and non-disruptive manner; competition against other companies; the negative impact on our ability to market our HA products due to the reclassification of HA products from medical devices to drugs in the United States by the FDA; failure to comply with the extensive government regulations related to our products and operations; enforcement actions if we engage in improper claims submission practices or in improper marketing or promotion of our products; the FDA regulatory process and our ability to obtain and maintain required regulatory clearances and approvals; and the other risks identified in the Risk Factors section of the Company’s public filings with the Securities and Exchange Commission (“SEC”), including Bioventus’ Annual Report on Form 10-K for the period ended December 31, 2020, as updated in our Quarterly Report on Form 10-Q for the quarter ended July 3, 2021 and as such factors may be further updated from time to time in Bioventus’ other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Bioventus’ website at ir.bioventus.com. Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement.

Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business.

Media Contact: Thomas Hill Bioventus 919-474-6715 [email protected]

Investor Inquiries: Dave Crawford Bioventus 919-474-6787 [email protected]

Source link

0 notes

market-insights-dbmr · 3 years ago

Text

Johanson Blizzard Syndrome In Depth Industry Analysis on Trends, Growth, Opportunities and Forecast till 2028

Johanson-Blizzard syndrome (JBS) is defined as an extremely rare genetic disorder which affects multiple organ systems of the body. Many symptoms are present at birth (congenital) or early childhood and the spectrum of potential features and physical findings associated with JBS is wide and varied and can differ dramatically from one person to another.

The countries covered in the Johanson Blizzard syndrome market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

Download Sample PDF Copy of Report@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-johanson-blizzard-syndrome-market

The major players covered in the Johanson Blizzard syndrome market report are Merck KGaA, Sanofi, Pfizer Inc, BD and Cadwell Industries, Inc among other domestic and global players. Osteoarthritic pain management treatment share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Johanson Blizzard Syndrome Market Scope and Market Size

The Johanson Blizzard syndrome market is segmented on the basis of symptoms and related disorders. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

· On the basis of symptoms, the Johanson Blizzard syndrome market is segmented into pancreatic insufficiency, tooth abnormalities and characteristic shape of the nose.

The Johanson Blizzard syndrome market is also segmented on the basis of related disorders into cystic fibrosis, Shwachman syndrome and Pearson marrow-pancreas syndrome.

List of Chapters:

1 Johanson Blizzard syndrome Market Overview 2 Global Johanson Blizzard syndrome Market Competitions by Manufacturers 3 Global Johanson Blizzard syndrome Capacity, Production, Revenue (Value) by Region (2021-2028) 4 Global Johanson Blizzard syndrome Supply (Production), Consumption, Export, Import by Region (2021-2028) 5 Global Johanson Blizzard syndrome Production, Revenue (Value), Price Trend by Type 6 Global Johanson Blizzard syndrome Market Analysis by Application 7 Global Johanson Blizzard syndrome Manufacturers Profiles/Analysis 8 Johanson Blizzard syndrome Manufacturing Cost Analysis 9 Industrial Chain, Sourcing Strategy and Downstream Buyers 10 Marketing Strategy Analysis, Distributors/Traders 11 Market Effect Factors Analysis 12 Global Johanson Blizzard syndrome Market Forecast (2021-2028) 13 Research Findings and Conclusion 14 Appendix

Get Full Table Of content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-johanson-blizzard-syndrome-market

Customization Available: Global Johanson Blizzard Syndrome Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing [email protected] . We are content with our glorious 99.9 % client satisfying rate.

Contact: Data Bridge Market Research US: +1 888 387 2818 UK: +44 208 089 1725 Hong Kong: +852 8192 7475 Email: [email protected]

0 notes

marketreserchnews · 5 years ago

Text

Covid19 update: Thoracic Surgery Devices Market will change the Future | Zoetis Services LLC.

Thoracic Surgery Devices Market study highlights detailed assessment of the Market and display Thoracic Surgery Devices market sizing trend by revenue & volume (if applicable), expert opinions, current growth factors, facts, and industry validated market development data. Few of the major competitors currently working in the global Thoracic Surgery Devices market are Bharat Biotech., Ceva, GlaxoSmithKline plc, Grifols, S.A, Zoetis Services LLC., Virbac. Sanofi, Merck Sharp & Dohme Corp., Emergent BioSolutions Inc, Integrated BioTherapeutics, Inc., Abbott, Avalon Pharma Private Limited, HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD, Pfizer Inc, among others.

Global thoracic surgery devices market is expected to register a substantial CAGR of 9.33% in the forecast period of 2019-2026.

Browse now Sample Copy or Full Report Index @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-thoracic-surgery-devices-market

Thoracic surgery devices are the medical instruments, components and devices designed for operating/treating the ailments of patient in relation to their chest. These surgical procedures deal with treatment of organs such as heart, lungs, and esophagus. Various surgical procedures included in thoracic surgery involve heart transplant, removal of parts affected due to cancer, coronary artery bypass, lung transplant and various others.

Market Drivers

Enhancement of innovations and adoption of advanced technologies for surgical methods and devices is expected to drive the growth of the market

Utilization of video-assisted surgical systems along with energy-based devices is expected to boost the growth of the market

High volume of facilities established for easier usage and implantation of cardiac rhythm management devices is expected to propel the growth of the market

Increasing volume of patients suffering from cardiovascular diseases along with lung disorders acts as a market driver

Market Restraints

Complications prevalent with thoracic surgeries such as hemorrhage, wound infection, pneumonia, respiratory failure and others is expected to hinder the growth of the market

Lack of awareness regarding the complications arising through video-assisted thoracic surgery (VATS) amid lack of skilled professionals also restricts the growth of this market in the forecast period

By Product (CRM & Cardiac Assist, Heart Valve Repair & Replacement, Heart Defect Closure, Cardiopulmonary Devices, Others), End-Users (Hospitals, Clinics, Ambulatory Surgery Centers, Others)

Relevant features of the study that is being offered with major highlights from the report:

1) Which companies are profiled in current version of the report? Can list of players be customizing based on regional geographies we are targeting.

Few of the major competitors currently working in the global thoracic surgery devices market are Medical Devices Business Services, Inc.; Olympus Corporation; KLS Martin Group; B. Braun Melsungen AG; Medtronic; OmniGuide Holdings, Inc.; biolitec AG; Intuitive Surgical; Scanlan International; Getinge AB among others.

2) What all regional break-up covered? Is it possible to add specific country or region of interest?

Currently, research report gives special attention and focus on following regions: Asia-Pacific, South America, North America, Europe and & Middle East & Africa

3) Can Market be broken down by different set of application and types?

Additional Thoracic Surgery Devices Market segmentation / Market breakdown is possible subject to data availability, feasibility and depending upon timeline and toughness of survey. However a detailed requirement needs to be prepared before making any final confirmation.

MAJOR TOC OF THE REPORT

Chapter One: Thoracic Surgery Devices Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Thoracic Surgery Devices Market Competition, by Players

Chapter Four: Global Thoracic Surgery Devices Market Size by Regions

Chapter Five: North America Thoracic Surgery Devices Revenue by Countries

Chapter Six: Europe Thoracic Surgery Devices Revenue by Countries

Chapter Seven: Asia-Pacific Thoracic Surgery Devices Revenue by Countries

Chapter Eight: South America Thoracic Surgery Devices Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Thoracic Surgery Devices by Countries

Chapter Ten: Global Thoracic Surgery Devices Market Segment by Type

Chapter Eleven: Global Thoracic Surgery Devices Market Segment by Application

Get Detailed Toc @ https://www.databridgemarketresearch.com/toc/?dbmr=global-thoracic-surgery-devices-market

Key Stakeholders Audience Covered:

In order to better analyze value chain/ supply chain of the Industry, a lot of attention given to forward and backward Integration of Thoracic Surgery Devices Market

- Thoracic Surgery Devices Manufacturers

- Thoracic Surgery Devices Distributors/Traders/Wholesalers

- Thoracic Surgery Devices Sub-component Manufacturers

- Industry Association

- Downstream Vendors

Data Bridge Market also provides customized specific regional and country-level reports, see below break-ups.

North America: United States, and Mexico.

South & Central America: Argentina, LATAM, and Brazil.

Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa.

Europe: UK, France, Italy, Germany, Spain and Russia.

Asia-Pacific: India, China, Japan, South Korea, Indonesia, Thailand, Singapore, and Australia.

Reasons for Buying this Thoracic Surgery Devices Report

1. Thoracic Surgery Devices market report aids in understanding the crucial product segments and their perspective.

2. Initial graphics and exemplified that a SWOT evaluation of large sections supplied from the Thoracic Surgery Devices industry.

3. Even the Thoracic Surgery Devices economy provides pin line evaluation of changing competition dynamics and retains you facing opponents.

4. This report provides a more rapid standpoint on various driving facets or controlling Thoracic Surgery Devices promote advantage.

5. This worldwide Thoracic Surgery Devices report provides a pinpoint test for shifting dynamics that are competitive.

Buy Full Copy of Thoracic Surgery Devices Market @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-thoracic-surgery-devices-market

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like West Europe, North America, MENA Countries, LATAM, Southeast Asia or Asia Pacific.

About Us:

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

Browse Related Report@

Neuroendoscopy Market

Offsite Sterilization Services Market

Osteoarthritic Pain Market

SPECT Probes Market

0 notes

davidjones3991-blog · 6 years ago

Link

#Global Osteoarthritic Pain Management Treatment Industry Analysis #Global Osteoarthritic Pain Management Treatment Market Research Report #Global Osteoarthritic Pain Management Treatment Research Report #Osteoarthritic Pain Management Treatment Market #Osteoarthritic Pain Management Treatment Research Report

0 notes

healthcaredbmrnews · 3 years ago

Link

The osteoarthritic pain management treatment market is expected to gain market growth at a potential rate of 6.75% in the forecast period of 2021 to 2028. Rise in the significant adoption of pain medications is the vital factor escalating the market growth.

#Osteoarthritic Pain Management Treatment Market

0 notes

your-dietician · 3 years ago

Text

DUROLANE® Among High-Molecular Weight Hyaluronic Acid

New Post has been published on https://depression-md.com/durolane-among-high-molecular-weight-hyaluronic-acid/

DUROLANE® Among High-Molecular Weight Hyaluronic Acid

DUROLANE is a single-injection osteoarthritis (OA) treatment that is lightly cross-linked and has the highest reported molecular weight of all US-approved HA products.1, 2

Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark. Synvisc-One is a registered trademark of Genzyme Corporation.

Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business.

Media Contact: Thomas Hill Bioventus 919-474-6715 [email protected]

Investor Inquiries: Dave Crawford Bioventus 919-474-6787 [email protected]

Source link

0 notes

your-dietician · 3 years ago

Text

Bone Therapeutics announces topline results from Phase III

New Post has been published on https://depression-md.com/bone-therapeutics-announces-topline-results-from-phase-iii/

Bone Therapeutics announces topline results from Phase III

REGULATED INFORMATION

No statistically significant difference in knee pain reduction between JTA-004, placebo and active comparator, 3 months after treatment; favorable JTA-004 safety profile similar to placebo and comparator

Prime focus on the continued development and expansion of its mesenchymal stromal cell based allogeneic cell and gene therapy platform

Management to host conference call today at 4pm CEST / 10am EST – details provided below

Gosselies, Belgium, 30 August 2021, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces that the Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004 did not meet the primary and consequently the key secondary endpoints.

The primary objective of the JTA-004 Phase III study was to demonstrate the efficacy of JTA-004 in reducing osteoarthritic knee pain compared to placebo as measured by the WOMAC® pain subscale three months after treatment. A key secondary objective was the comparison between JTA-004 and comparator Hylan G-F 20 in knee pain relief at month 3. Despite JTA-004’s favorable safety profile, the study did not achieve its main objectives as no statistically significant difference in pain reduction could be observed between any of the treatment, placebo and comparator groups, with all treatment arms showing similar efficacy.

A statistically significant difference in favor of JTA-004 and the active comparator versus placebo was seen in a post-hoc analysis in a subset of patients with higher pain scores at entry.

The Company, in collaboration with existing and potential partners, will consider the options for the future of JTA-004 development.

“The execution of the study was flawless and a good safety profile was observed in line with previous results. These JTA-004 efficacy results are disappointing. Knee osteoarthritis studies are recognized across the industry to be challenging to evaluate. They are also frequently complicated by a high placebo effect. We will continue to analyze the data and will consider potential next steps,” said Miguel Forte, Chief Executive Officer of Bone Therapeutics. “We are now fully committed to the clinical development of our advanced MSC allogeneic cell and gene therapy platform. Bone Therapeutics is concentrating on the development of this platform for the large market of orthopedic indications, with ALLOB. The progress with this platform has enabled us to expand it to other indications, including immunomodulation.”

Bone Therapeutics is focused on the development of its core assets, the allogeneic cell therapy platform, including ALLOB. ALLOB is currently being evaluated in a randomized, double-blind, placebo-controlled Phase IIb study in 178 patients with fresh tibial fractures at risk of delayed or non-union. 5% to 10% of complicated long bone fractures evolve to delayed union and non-union. This study will assess the potential for a single percutaneous injection of ALLOB to accelerate fracture healing and prevent late-stage complications in these patients. Recruitment is expected to be completed in the first half of 2022 and topline results by the end of 2022. Should the pandemic continue, Bone Therapeutics may have to re-evaluate these timelines and, in that eventuality, will communicate again to the market.

Bone Therapeutics is intensifying its efforts to expand its preclinical and clinical pipeline with additional indications by enhancing and “professionalizing” the therapeutic capacity of its cell and gene therapy platform. This includes the development of a next generation of genetically engineered mesenchymal stromal cells (MSC) and the use of highly scalable and versatile cell sources such as induced pluripotent stem cells (iPSC).

Conference call

The management of Bone Therapeutics will host a conference call today at 4:00 pm CEST / 10:00 am EST. To participate in the conference call, please select your dial-in number from the list below quoting the conference ID 825 1002 3115#:

Belgium: +32 2 290 9360 France: +33 1 7095 0103 United Kingdom: +44 208 080 6592 United States: +1 646 876 9923

About JTA-004 and Phase III knee osteoarthritis study

JTA-004 is Bone Therapeutics’ next generation of intra-articular injectable for the treatment of osteoarthritic pain in the knee. It consists of a unique mix of hyaluronic acid – a natural component of knee synovial fluid, plasma proteins, and a fast-acting analgesic. JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain.

The JTA-004 Phase III study is a controlled, randomized, double-blind trial. It evaluates the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee, compared to placebo or Hylan G-F 20, the leading osteoarthritis treatment on the market. The study is being conducted in 22 centers across six European countries as well as Hong Kong. More than 700 patients with mild to moderate symptomatic knee osteoarthritis were treated in this study.

About Knee Osteoarthritis

Osteoarthritis (OA), also known as degenerative joint disease, is the most common chronic joint condition in which the protective cartilage in the joints progressively break down resulting in joint pain, swelling, stiffness and limited range of motion. The knee is one of the joints that are mostly affected by osteoarthritis, with an estimated 250 million cases worldwide.

The prevalence of knee osteoarthritis (KOA) is expected to increase in the coming years due to increasingly aging and obese population. Currently, there is no cure for KOA and treatments focus on relieving and controlling pain and symptoms, preventing disease progression, minimizing disability, and improving quality of life. Most drugs prescribed to KOA patients are topical or oral analgesics and anti-inflammatory drugs. Ultimately, severe KOA leads to highly invasive surgical interventions such as total knee replacement.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a diversified portfolio of cell therapies at different stages ranging from pre-clinical programs in immunomodulation to mid stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics’ core technology is based on its cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics’ scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company has initiated patient recruitment for the Phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at www.bonetherapeutics.com.

For further information, please contact:

Bone Therapeutics SA Miguel Forte, MD, PhD, Chief Executive Officer Jean-Luc Vandebroek, Chief Financial Officer Tel: +32 (0)71 12 10 00 [email protected]

For Belgian Media and Investor Enquiries: Bepublic Catherine Haquenne Tel: +32 (0)497 75 63 56 [email protected]

International Media Enquiries: Image Box Communications Neil Hunter / Michelle Boxall Tel: +44 (0)20 8943 4685 [email protected] / [email protected]

For French Media and Investor Enquiries: NewCap Investor Relations & Financial Communications Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouillé Tel: +33 (0)1 44 71 94 94 [email protected]

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Source link

0 notes